scholarly journals Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): A retrospective analysis

2017 ◽  
Vol 28 ◽  
pp. v535-v536
Author(s):  
L. Incorvaia ◽  
G. Badalamenti ◽  
E. Musso ◽  
I. de luca ◽  
A. Casarin ◽  
...  
2019 ◽  
Vol 89 (6) ◽  
pp. AB320-AB321
Author(s):  
Christopher A. Macdonnell ◽  
Jennifer J. Telford ◽  
Cherry Galorport ◽  
Eric Lam ◽  
Fergal Donnellan ◽  
...  

2005 ◽  
Vol 61 (5) ◽  
pp. AB277
Author(s):  
Gloria Fernández-Esparrach ◽  
Enrique Vázquez-Sequeiros ◽  
Lidia Argüello ◽  
Manel Solé ◽  
Maria Pellisé ◽  
...  

BMC Cancer ◽  
2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Piotr Rutkowski ◽  
Elżbieta Bylina ◽  
Anna Klimczak ◽  
Tomasz Świtaj ◽  
Sławomir Falkowski ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Margaret von Mehren ◽  
Michael C. Heinrich ◽  
Hongliang Shi ◽  
Sergio Iannazzo ◽  
Raymond Mankoski ◽  
...  

Abstract Background Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). Methods This retrospective analysis compared efficacy of avapritinib in patients enrolled in the NAVIGATOR phase 1 trial (NCT02508532) with the efficacy of other tyrosine kinase inhibitors (TKIs) in patients with unresectable/metastatic PDGFRA D842V-mutant GIST enrolled in a retrospective natural history study (Study 1002). The primary endpoint was overall survival (OS) from the start of reference treatment (avapritinib for NAVIGATOR patients or first-line TKI for treatment of unresectable/metastatic GIST for Study 1002 patients); the secondary endpoint was progression-free survival (PFS). Adjusted Kaplan–Meier survival curves were compared by Cox regression. Results Fifty-six (NAVIGATOR) and 19 (Study 1002) patients with PDGFRA D842V-mutant GIST were evaluated; of the 56 patients from NAVIGATOR, a subgroup of patients treated with either 300 mg (recommended phase 2 dose) or 400 mg (maximum tolerated dose) avapritinib starting dose (n = 38) were analyzed separately. Patient characteristics were adjusted for imbalances by propensity score between the study groups. Inverse probability of treatment weighting-adjusted Kaplan–Meier analysis of OS showed median OS was not reached for NAVIGATOR patients treated with any of the avapritinib doses tested and was 12.6 months for Study 1002 patients; OS rate at 6/48 months was 100%/63% in NAVIGATOR and 56%/17% in Study 1002 (P = 0.0001). In the 300/400 mg subgroup, adjusted OS rates at 6/36 months were 100%/73 and 68%/20% in Study 1002 (P = 0.0016). Adjusted median PFS was 29.5 months in NAVIGATOR and 3.4 months in Study 1002. Conclusions In this indirect, retrospective analysis, avapritinib demonstrated more durable survival outcomes compared with other TKIs in patients with unresectable/metastatic PDGFRA D842V-mutant GIST. Trial registration The NAVIGATOR trial was registered at ClinicalTrials.gov as per July 2015, Identifier: NCT02508532.


2015 ◽  
Vol 48 (6) ◽  
pp. 473-480
Author(s):  
Takehito Yamamoto ◽  
Akira Miki ◽  
Kazuyuki Okada ◽  
Chihiro Ichikawa ◽  
Ryosuke Matsuoka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document